Veeva Systems Inc. (VEEV) Stock Valuation — PE Analysis
Medical - Healthcare Information Services · NYSE
Current Price
$159.54
PE Ratio (TTM)
27.7x
Intrinsic Value
$213.79
+25.4% margin of safety
COMPETITIVE MOAT
↑Deep Pharma Cloud Integration
Veeva's comprehensive cloud suite is deeply embedded in biopharmaceutical workflows, creating significant switching costs for customers. This integration is further strengthened by new AI capabilities.
↑AI-Powered Workflow Automation
The introduction of Falcon AI agents and their integration into existing platforms like CRM enhances efficiency. This advanced automation makes Veeva's solutions indispensable for drug development and commercialization.
↑Strong Customer Relationships & Data
Long-standing relationships and the vast amount of proprietary data within Veeva's ecosystem create a network effect. This data advantage fuels AI development and customer stickiness.
INVESTMENT RISKS
↓Intensifying AI Competition
While Veeva is pushing AI, the broader tech sector's rotation away from tech stocks suggests increased competition and potential commoditization of AI features. Competitors may offer similar AI solutions.
↓Execution of AI Strategy
The success of Veeva's AI push, particularly with Falcon agents, hinges on seamless integration and demonstrable value. Any missteps in execution could impact customer adoption and future growth.
↓Regulatory Landscape Shifts
The biopharmaceutical industry is heavily regulated. Changes in regulatory requirements could necessitate significant platform updates, potentially impacting Veeva's development roadmap and costs.
Base case
VEEV base case PE valuation
A base case PE valuation for VEEV estimates a fair value of about $213.79 per share, against a current price of $159.54. The model assumes 12.8% annual earnings growth, a 28x target PE multiple, and a 10% discount rate.
Intrinsic Value
$213.79
Margin of safety
+25.4%
Expected annual return
+6.0%
Base case assumptions: 12.8% annual earnings growth, 28x target PE, 10% discount rate, 5 year projection. Data as of 2026-06-12.
This base case uses default assumptions and is not financial advice. The fair value changes significantly when the target PE or earnings growth rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the VEEV PE valuation
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for Veeva Systems Inc. respond.
Open PE Calculator for VEEVCompany Overview
Veeva Systems Inc. is a leading provider of cloud-based software solutions, exclusively dedicated to the global life sciences industry. Its extensive operational presence spans across North America, Europe, the Asia Pacific region, the Middle East, Africa, and Latin America. The company's product portfolio is primarily structured around two major offerings. First, the Veeva Commercial Cloud delivers an integrated suite of software, data, and analytics tools designed to optimize commercial operations. This includes vital applications such as Veeva Customer Relationship Management (CRM) and its specialized Medical CRM, Veeva Closed Loop Marketing (CLM), sophisticated analytics via Veeva CRM MyInsights, approved email communication with Veeva CRM Approved Email, digital engagement tools like Veeva CRM Engage, commercial alignment through Veeva Align, event management capabilities with Veeva CRM Events Management, data warehousing solutions (Veeva Nitro), data services (Veeva OpenData, Veeva Link), master data management (Veeva Network), advanced analytical insights (Veeva Crossix, Veeva Data Cloud), and patient engagement platforms (MyVeeva for Patients). Secondly, Veeva Vault provides a robust collection of cloud-native enterprise content and data management applications. These applications are engineered to support both critical commercial functions—encompassing sales, marketing, and medical content and communications—and comprehensive research and development processes, including clinical trials, regulatory compliance, quality management, and patient safety. Beyond its software, Veeva offers a wide array of professional and support services. These range from strategic implementation and deployment planning, project management, and detailed requirements analysis to solution design and configuration. They also include system environment management and deployment, expert consulting for business process transformation related to Veeva solutions, technical guidance on data migration and systems integrations, comprehensive training programs, and ongoing managed services such as outsourced systems administration. Tracing its origins, the company was incorporated in 2007 as Verticals onDemand, Inc., and subsequently rebranded to Veeva Systems Inc. in April 2009. Its corporate headquarters are situated in Pleasanton, California.
Financial Metrics — VEEV PE Stock Valuation Data
PE Ratio (TTM)
27.7x
PEG Ratio
1.40
Earnings Yield
3.61%
ROE (TTM)
13.4%
Revenue/Share (TTM)
$20.32
Debt/Equity
0.01x
Frequently Asked Questions
What is the PE ratio of VEEV?
The trailing twelve-month PE ratio of VEEV reflects how much investors pay per dollar of Veeva Systems Inc.'s earnings. This metric is most useful when compared to Medical - Healthcare Information Services peers and the company's own historical range.
Is VEEV overvalued based on PE ratio?
VEEV's PE of 27.7x combined with a PEG ratio of 1.40 provides a growth-adjusted perspective. A PEG near 1.0 suggests the PE ratio is reasonably justified by the earnings growth rate. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Medical - Healthcare Information Services, a DCF analysis may be more appropriate.
How do I value VEEV stock using PE ratio?
To value Veeva Systems Inc. using PE: (1) Compare the current PE (27.7x) against the Medical - Healthcare Information Services median to assess relative pricing, (2) check the PEG ratio (1.40) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
What is the PEG ratio of VEEV?
VEEV's PEG ratio is 1.40, calculated by dividing the PE ratio (27.7x) by the expected earnings growth rate. A PEG near 1.0 suggests the stock is fairly priced relative to growth. Note that PEG accuracy depends on the reliability of growth estimates.
Should I use PE ratio or DCF for VEEV stock valuation?
PE ratio gives a quick relative read — how VEEV is priced versus Medical - Healthcare Information Services peers. DCF provides an absolute value based on projected free cash flows. For the most reliable valuation, use PE as a quick comparability screen and DCF for a deeper fundamental analysis. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
Learn More
- See VEEV DCF Valuation → — Intrinsic value via Discounted Cash Flow analysis
- PE Methodology — Step-by-step guide to PE ratio stock valuation
- DCF Methodology — Guide to discounted cash flow analysis
- PE Ratio — Understanding the price-to-earnings ratio
- Intrinsic Value — How to evaluate stock fair value
Related PE Valuations
All Healthcare valuationsP/E and DCF value VEEV with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-06-12. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.